中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
12期
1520-1521
,共2页
黄娟%张韶英%段晓宇%管斯斯
黃娟%張韶英%段曉宇%管斯斯
황연%장소영%단효우%관사사
糖尿病肾病%内皮素%尿微量白蛋白排泄率%贝前列素钠
糖尿病腎病%內皮素%尿微量白蛋白排洩率%貝前列素鈉
당뇨병신병%내피소%뇨미량백단백배설솔%패전렬소납
Diabetic nephropathies%Endothelin%Urinary albumin excretion rate%Beraprost sodium
目的 观察贝前列素钠对糖尿病肾病患者临床疗效及血浆内皮素1水平的影响.方法 选择2型糖尿病患者75例,根据是否合并糖尿病肾病将其分为无肾病组(27例)和肾病组(48例).将肾病组患者完全随机分为对照组和研究组,各24例.在常规治疗的基础上,研究组另用贝前列素钠20μg/次,1次/d,口服.用药前及用药后8周测定3组糖尿病患者血浆内皮素1水平、尿微量白蛋白及尿白蛋白排泄率(UAER).结果 肾病组和无肾病组用药前血浆内皮素1分别为(138±9)ng/L和(67±3)ng/L,差异有统计学意义(P＜0.01).研究组应用贝前列素钠后血浆内皮素1和UAER明显低于对照组,组间差异有统计学意义[血浆内皮素1:(72±4)比(126±9) ng/L,P＜0.05;UAER:(89±27)比(109±35) mg/24 h,P＜0.01].结论 内皮素1水平升高在糖尿病肾病的发病中发挥重要作用.贝前列素钠治疗可纠正糖尿病肾病患者血浆内皮素1平衡失调,改善糖尿病肾病内皮功能,降低尿蛋白,对糖尿病肾病有保护作用.
目的 觀察貝前列素鈉對糖尿病腎病患者臨床療效及血漿內皮素1水平的影響.方法 選擇2型糖尿病患者75例,根據是否閤併糖尿病腎病將其分為無腎病組(27例)和腎病組(48例).將腎病組患者完全隨機分為對照組和研究組,各24例.在常規治療的基礎上,研究組另用貝前列素鈉20μg/次,1次/d,口服.用藥前及用藥後8週測定3組糖尿病患者血漿內皮素1水平、尿微量白蛋白及尿白蛋白排洩率(UAER).結果 腎病組和無腎病組用藥前血漿內皮素1分彆為(138±9)ng/L和(67±3)ng/L,差異有統計學意義(P＜0.01).研究組應用貝前列素鈉後血漿內皮素1和UAER明顯低于對照組,組間差異有統計學意義[血漿內皮素1:(72±4)比(126±9) ng/L,P＜0.05;UAER:(89±27)比(109±35) mg/24 h,P＜0.01].結論 內皮素1水平升高在糖尿病腎病的髮病中髮揮重要作用.貝前列素鈉治療可糾正糖尿病腎病患者血漿內皮素1平衡失調,改善糖尿病腎病內皮功能,降低尿蛋白,對糖尿病腎病有保護作用.
목적 관찰패전렬소납대당뇨병신병환자림상료효급혈장내피소1수평적영향.방법 선택2형당뇨병환자75례,근거시부합병당뇨병신병장기분위무신병조(27례)화신병조(48례).장신병조환자완전수궤분위대조조화연구조,각24례.재상규치료적기출상,연구조령용패전렬소납20μg/차,1차/d,구복.용약전급용약후8주측정3조당뇨병환자혈장내피소1수평、뇨미량백단백급뇨백단백배설솔(UAER).결과 신병조화무신병조용약전혈장내피소1분별위(138±9)ng/L화(67±3)ng/L,차이유통계학의의(P＜0.01).연구조응용패전렬소납후혈장내피소1화UAER명현저우대조조,조간차이유통계학의의[혈장내피소1:(72±4)비(126±9) ng/L,P＜0.05;UAER:(89±27)비(109±35) mg/24 h,P＜0.01].결론 내피소1수평승고재당뇨병신병적발병중발휘중요작용.패전렬소납치료가규정당뇨병신병환자혈장내피소1평형실조,개선당뇨병신병내피공능,강저뇨단백,대당뇨병신병유보호작용.
Objective To observe the effect of beraprost sodium on diabetic nephropathy (DN) patients and to observe if beraprost sodium in patients with diabetic nephropathy affects the level of endothelin-1.Methods Totally 75patients with type 2 diabetes with or without diabetic nephropathy were divided into non-diabetic nephropathy group (n =27) and diabetic nephropathy group (48 cases).Nephrotic patients were randomly divided into control group and study group with 24 cases in each group.Determination of diabetic patients plasma levels of endothelin-1,beraprost sodium and plasma endothelin-1,urinary albumin and urinary albumin excretion rate (UAER) levels was made.Results Plasma endothelin-1 in nephropathy group was significantly higher than that in non-nephropathy group and the difference was statistically significant (P ＜ 0.01).Beraprost sodium,plasma endothelin-1 and UAER were significantly lower than those in control group and the difference was statistically significant.Conclusions The level of ET-1 may play an important role in the onset of diabetic nephropathy.Beraprost sodium can improve endothelial function and decrease urine protein in diabetic nephropathy.
